TQB 2102
Alternative Names: HER2 dual-antibody-drug conjugate - Chia Tai Tianqing Pharmaceutical Group; TQB-2102Latest Information Update: 03 Sep 2025
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer; HER2 positive breast cancer
- Phase II Adenocarcinoma; Gynaecological cancer; Non-small cell lung cancer
- Phase I/II Biliary cancer
- Phase I Cancer
Most Recent Events
- 01 Sep 2025 Henan Cancer Hospital plans a phase II trial for HER2 positive breast cancer (Neoadjuvant therapy, Early-stage disease) in China (IV, Infusion) (NCT07136974)
- 23 Jun 2025 Phase-III clinical trials in HER2-negative-breast-cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT07003074)
- 09 Jun 2025 Chia Tai Tianqing Pharmaceutical plans a phase-III trial for HER2- positive breast cancer (Neoadjuvant therapy) in China (IV, injection) in August 2025 (NCT07043725)